Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants

Warning

This publication doesn't include Faculty of Education. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

ČEŠKOVÁ Eva

Year of publication 2016
Type Article in Periodical
Magazine / Source EXPERT OPINION ON PHARMACOTHERAPY
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.tandfonline.com/doi/full/10.1080/14656566.2016.1219340?scroll=top&needAccess=true
Doi http://dx.doi.org/10.1080/14656566.2016.1219340
Field Pharmacology and pharmaceutical chemistry
Keywords Depressive disorder; pharmacoresistance; multimodal; multifunctional antidepressants; pharmacogenomic tests
Description Major depressive disorder (MDD) is a widespread disease, with a lifetime prevalence of 15% and an annual incidence of approximately 7%. It is associated with significant costs in quality of life, loss of work productivity, and a high risk of mortality. It is predicted to become the leading cause of disability in Western countries by 2030.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.